Dr. Jyoti Srivastava is a distinguished expert in the biology of cancer and inflammatory diseases, with over 15 years of experience spanning academia, biotechnology, and leading cancer research institutions. Her work is at the forefront of targeted therapeutics, with a deep focus on tumor biology, drug resistance, and personalized medicine. Dr. Srivastava has pioneered innovative strategies across a range of malignancies, including melanoma, hepatocellular carcinoma, lymphoma, and inflammatory conditions. Her research integrates targeted cancer therapy with immune-oncology, biomarker discovery, and translational science to develop precision oncology solutions. Through her deep understanding of molecular mechanisms and disease complexity, she continues to shape next-generation therapies, particularly in areas of unmet clinical need. Dr. Srivastava’s vision is transforming cancer care by advancing novel, personalized, and resistance-overcoming therapeutic strategies.

Research Interest(s): Cancer Biology, Metastasis, Targeted Therapeutics, Drug Resistance, Chronic Inflammatory Diseases, Liver Cancer, Melanoma, Lymphoma, MASH/NASH, Cell Signalling, Disease Mechanisms, Drug Discovery, Drug Development, RNAi Therapeutics, Small Molecules